The Global Market for Point of Care Diagnostics

Pharma Business Daily
Claim your FREE trial subscription!

Pharmaceutical:

The Global Market for Point of Care Diagnostics

Espicom Business Intelligence
Management Report - December 2 December 2007

The 2nd edition of this two volume guide from Espicom provides an extensive competitive comparison and evaluation of major and emerging companies, sets the POC markets in context and provides market valuations as well as critical appraisal of research & innovation. Providing…
Extensive competitive comparison and evaluation of major and emerging companies
Market valuation and POC markets in context
Critical appraisal of research & innovation

Covering…
Blood Glucose
Cardiology
Coagulation
Blood Gas/Electrolytes
Infectious Diseases
Pregnancy/Fertility
Clinical Chemistry/Urinalysis
Haematology
Drugs of Abuse
Tumour Markers
Data Management
Emerging Research Trends The global point of care (POC) testing market is currently estimated to be worth US$11.3 billion in 2007 and is growing at 11% a year. POC testing accounts for approximately 34% of the US$33.6 billion global in-vitro diagnostic (IVD) testing market. Diagnostic testing accounts for only between 1-2% of government healthcare expenditures worldwide, yet influences between 60-70% of healthcare decisions.

The changing face of the POC industry
Double digit growth expectancy for POC testing has spurred considerable investment and interest from the industry. Although the POC sector is, in many respects, relatively immature it is already characterised by a great deal of M&A activity.

The most active acquirer at present is Inverness Medical Innovations which has made multiple acquisitions in recent years, buying up leading companies such as Biosite, Cholestech and Hemosense among others, and providing the company with a significant presence in cardiology and other segments.

Unsurprisingly, the POC market has also seen moves by large multinationals which previously had no presence in the IVD market. Siemens, for example, made major acquisitions to establish its diagnostics division, with Diagnostics Products Corporation and Bayer Diagnostics coming under the Siemens umbrella in 2006 at a cost of US$5.7 billion. The company has also just completed the acquisition of leading diagnostics company, Dade Behring, in a transaction valued at approximately US$7 billion.

3M Health Care also established a new medical diagnostics business in March 2007 and has already entered alliances with Response Biomedical and Gen-Probe in its aim to become a leader in screening for hospital and community-acquired infectious diseases. Strategic alliances such as this are a key feature of this rapidly evolving market, with many combining the innovations of smaller companies with the strong established distribution channels of large multinationals. A positive outlook for this rapidly growing sector
Drivers of growth

Healthcare Trends
Rising health costs have created new expectations in hospitals including shortened patient stays, and a movement from an inpatient to an outpatient or ambulatory setting.

As hospitals become treatment centres for the acutely ill and no longer serve primarily as diagnostic centres, the subsequent change in the patient's hospital stay and patient acuity have placed demands on the laboratory to deliver information in a manner which will facilitate rapid diagnosis and treatment. Because these demands have compressed the timeframe for performing testing, shorter turn around times and an increase in the volume of stat testing have become a necessity.

Social Pressure
Many patients today have greater medical knowledge, more money and greater expectations of healthcare services. They are demanding faster, more effective treatment and want greater control of their health.

Industry Pressure
Manufacturers are driving growth through the development of diagnostics instruments and tests that are simple and easy to use specifically for the POC environment. Many of the devices have data management capabilities to enable them to be linked to hospital information systems for the capture of patient data.

Technology Advancements
High-quality lab tests are now available at the point of care with smaller test systems suitable for POC environments and automated features of new POC instruments.
Wider test menus – a greater variety of tests have been developed for POC instruments.
Increase in the availability of home-testing devices.
Increased use of data management tools to handle POC test data and costs throughout the healthcare system.
Quality Control – advances in software to either automate quality control or alert operators to perform QC before a patient sample is analysed.
Future multiplex systems offering the promise of more cost-effective testing with several parameters measured from just one sample.

Future developments...

It is clear that technological advancements in POC equipment will be a future growth driver in the POC market. Various companies are developing multiplex assay systems which enable the simultaneous measurement of numerous analytes from one small sample. This represents a major advancement in POC testing and offers the opportunity of lower costs and a reduction in the number of tests performed.

Broad interest in pharmacogenetic testing is developing rapidly as clinical laboratories, physicians, payers, patients, and pharmaceutical companies seek to provide the most appropriate treatment for each patient, while mitigating the high costs of healthcare and drug development. Advances in nucleic acid testing technologies have contributed to this growing interest by enabling rapid, multiplex genotyping analysis, which is required for widespread adoption of pharmacogenetic testing by clinical laboratories.

Volume I: Company Analyses

Volume I of the report provides extensive company information on 80 leading companies focusing on:
Product portfolio
Research programmes
Who’s working with whom?

The POC testing market comprises three high growth sectors:
Consumer self-testing
Primary care laboratory testing
Hospital testing
The POC market for rapid diagnostic products consists primarily of small and medium sized, non-centralised laboratories and testing locations such as POL’s, specialist mobile clinics, emergency rooms and some rapid-response laboratories in larger medical centres. This market is dominated by leading manufacturers such as Roche Diagnostics, Bayer Healthcare, Inverness Medical Innovations and Abbott Laboratories.
LEADING COMPANIES COVERED IN VOLUME I

3M Medical Diagnostics
Abaxis
Abbott Diagnostics
Acrongenomics
Aerscher Diagnostics
Alfa Scientific Designs
Amnisure International
Analyte Works Ltd.
Arkray
At First Diagnostic
Audit Diagnostics
Axis Shield
British Biocell International
BBI Enzymes
BD Diagnostics
Beckman Coulter
Biolytical Laboratories
Biomerica
Biomérieux
Bio-Rad Laboratories
Biosafe
Branan Medical
Care Products
Chembio Diagnostics
Chempaq
Church & Dwight
Diagnostic Test Group
(RAC Medical)
Eumed Biotechnology
Fisher Healthcare
Flexsite Diagnostics
Genzyme Diagnostics
Helena Laboratories
Hema Diagnostic Systems
Home Access Health Corp
Horiba Abx
IND Diagnostic
Instrumentation Laboratory
International Technidyne Corp
Inverness Medical Innovations
Iris Diagnostics
Jant Pharmacal
Lifestyle Choices Ltd
Medmira Laboratories
Menarini Diagnostics
Medtronic
Nanogen
Nova Biomedical
Omega Pharma
Orion Diagnostica
Orsense
Ortho-Clinical Diagnostics
Opti Medical
Polymedco
Polymer Technology Systems
Prima Biomedical
PreMD Inc
Princeton Biomeditech
Probe Scientific
Proteome Systems
Quest Diagnostics
Quidel Corporation
Radiometer
Remel
Response Biomedical Corp
Roche Diagnostics
Rohto Pharmaceutical
Runbio Biotech
SA Scientific
Siemens Medical Solutions Diagnostics
Sienco
Stanbio Laboratory
Syntron Bioresearch
Sysmex
Telcor
Tosoh Bioscience
Trinity Biotech
Via Medical
Waypoint Biomedical

Volume II: Market Sectors
Volume II of the report looks more closely at the issues and markets as a whole and focuses on current and novel development in the following key sectors:

Blood Glucose
Cardiology
Blood Gas/Electrolytes
Coagulation
Haematology
Infectious Diseases
Pregnancy/Fertility
Drugs of Abuse
Tumour Markers
Clinical Chemistry/Urinalysis

Currently, the consumer self-testing market is by far the largest segment of the POC diagnostics market, and mainly comprises blood glucose testing and pregnancy testing, with blood glucose testing accounting for the lion’s share. Fuelled by an ageing population and obesity, the number of people with diabetes is rising worldwide and it is now the fourth leading cause of death in most developed countries.

Beyond blood glucose monitoring we believe the fastest growing segments in the POC testing market are infectious disease testing and cardiac testing owing to the increased number of tests available and greater demand for such tests. The infectious disease testing market is primarily being driven by the increasing incidence of certain diseases, including viral hepatitis, respiratory syncytial virus (RSV), influenza, tuberculosis, HIV and other STDs, as well as the rapid rise in hospital-acquired infections (HAIs).

In the cardiac segment, the global need for anticoagulation treatment and monitoring is expected to double within the next decade. Currently, an estimated 7-8 million patients worldwide, including 3.9 million in the US, take oral anticoagulants such as warfarin to help reduce the body's chances of forming harmful blood clots.
In addition to the companies in Vol I, there is development coverage of companies in Vol. II which include:
Abbott Diabetes Care
Advanced BioSensors
AiMedics
Bayer
Calisto Medical
DexCom
Diabetech
Echo Therapeutics
Fovi Optics Inc
Freedom Meditech
Glucolight
Glucocon
GluMetrics
Integrity Applications
Kumetrix
Lein Applied Diagnostics
Lifescan
LighTouch Medical
Luminous Medical
Medtronic Diabetes
Menarini Diagnostics
Nanosphere
NIR Diagnostics
NIBGM
Oculir
OrSense
Pelikan Technologies
Pindi Products
Sensors for Medicine & Science
Sensys Medical
SpectRx
Synthetic Blood International (SYBD)
Veralight

Number of pages - 1325

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.